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Abstract: There is a long-standing debate over whether single or bilateral lung transplant provides better
short and long-term clinical outcomes. We performed a detailed PubMed search on relevant clinical research
publications on single (SLT) and bilateral lung transplantation (BLT). We included studies that were published
before and after the implementation of the lung allocation score (LAS). We reviewed disease-specific shortand long-term outcomes associated with each transplantation technique. The majority of published studies
are retrospective cohort studies that use institutional data or large patient registries. Outcomes associated
with transplantation technique vary by disease specific indication, age, and patient severity. Over the past
decade, the relative proportion of bilateral lung transplantation has increased. Increasing adoption of bilateral
lung transplant likely reflects the general acceptance of several advantages associated with the technique.
However, making a clear, evidence-based decision is difficult in light of the fact that there has never been and
probably never will be a randomized trial. Our institutional preference is bilateral lung transplant. However,
consideration for the technique should still be made on a case-by-case basis.
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Introduction
Since the first successful isolated lung transplant performed
by Dr. Joel Cooper at the University of Toronto in 1983,
lung transplantation has been considered an optimal therapy
for multiple causes of end stage pulmonary disease (1).
The initial isolated transplant operations were single lung
transplants performed on patients with severe idiopathic
pulmonary fibrosis (IPF). Since then, lung transplantation
has been more heavily utilized to treat patients with
multiple conditions including interstitial lung disease
(ILD), chronic obstructive pulmonary disease (COPD),
cystic fibrosis (CF), pulmonary hypertension, and more (2).
Over the past several decades, changes in donor selection,
postoperative care, and immunosuppression therapy
have broadened the use of lung transplant and improved
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outcomes for transplant recipients (3). While new guidelines
have been created to help guide transplant candidate
selection and management, there is still substantial debate
surrounding the utilization of single versus bilateral lung
transplantation in patients eligible for either strategy (2,4,5).
To date, much of the decision-making regarding use of
single versus bilateral lung transplant is based on individual
institutional case series experience or retrospective reviews
of large lung transplant registries. There is a lack of high
quality, prospective data to provide clear criteria favoring
single or bilateral lung transplantation when either strategy
is possible. Furthermore, there is a lack of consensus on the
philosophical dilemma: should a bilateral operation with
better palliation be offered to fewer patients, or should a
lesser unilateral operation be offered to more recipients?
The purpose of this chapter is to review the existing
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literature regarding single and bilateral lung transplantation.
Specifically, this review will highlight the following subjects:
 Disease-specific indications for single (SLT) vs.
bilateral lung transplantation (BLT), with a focus on
emphysema and pulmonary fibrosis;
 Impact of procedure type on post-transplantation
functional status;
 Impact of procedure type on post-transplantation
quality of life (QOL);
 Chronic rejection after lung transplantation;
 Ethical challenges facing the choice between single
and bilateral transplants;
 The novel strategy of “staged BLT (SBLT)”.
Disease-specific indications for lung
transplantation
There is a wide variety of indications for lung
transplantation, including end-stage COPD, ILD,
pulmonary hypertension, CF and bronchiectasis and
others (2). Because patients with septic lung disease
(including CF and bronchiectasis) almost always undergo
BLT due to the infectious risk posed by the retained
native lung, they will not be discussed further in this
chapter (6). The International Society for Heart and Lung
Transplantation (ISHLT) provides the most comprehensive
data on long-term survival associated with BLT and SLT for
all recipients (7). They collect data from 256 lung transplant
and 180 heart-lung transplant centers, and represent an
estimated 75% of international thoracic transplant activity.
The registry is ideal for examining longitudinal trends,
as the registry requires submission of follow-up data on
a yearly basis. In the 2017 ISHLT report summarizing
survival trends from 1990–2015, recipients of a lung
transplantation operation had a median survival of 6.0 years.
In unadjusted analysis, BLT recipients had better survival
post-transplant compared to SLT recipients. This difference
was first seen at 1 year post-op, but increased over a 14-year
follow-up period. Survival for BLT and SLT groups were
90% and 88% at 3 months, 82% and 78% at 1 year, 69%
and 61% at 3 years, 59% and 48% at 5 years, and 41% and
23% at 10 years, respectively. That high level comparison
simply begins the discussion, but there are multiple issues of
selection bias and confounding that cloud the comparison
of single or bilateral transplantation outcomes. Additional
literature has focused on short and long-term outcomes
associated with transplantation type within subgroups
of patients with specific diagnoses. Much of the existing
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literature examines the use of SLT and BLT in patients with
either advanced COPD or IPF.
COPD
Emphysema (which encompasses COPD and alpha-1
antitrypsin deficiency) has been the most common
indication for lung transplantation (2). The first successful
experience with transplantation in the COPD population
involved isolated SLT, initially described by Dr. Joel Cooper
and his team (1). However, with the development of BLT
and improvements in technique, BLT has received increased
clinical adoption and use in patients with COPD (6,8). The
prevailing physiologic reasoning supporting use of BLT
is that the technique reduces the risk of early ventilation/
perfusion mismatch and eliminates the issue of subsequent
hyperinflation in the unresected emphysematous native
lung that occurs after SLT (8). During the accumulation
of the early experience, there was a tendency to offer BLT
to younger patients with the notion that they might have
greater physiologic reserve to be able to withstand the
increased stress of a more prolonged surgery (1,4,6). That
selection bias might have also burdened the SLT cohort
with an older and frailer group of patients who would
be at greater risk for premature death regardless of the
differential contribution of SLT versus BLT.
Meyer and colleagues in 2001 performed one of the
early index studies comparing BLT and SLT in the COPD
population (4). Using the ISHLT/United Network
for Organ Sharing (UNOS) registry, they performed a
retrospective analysis of patients with COPD undergoing
lung transplantation. They attempted to study the
correlation between transplantation technique (SLT
vs. BLT) and survival, stratified by age (41–50, 51–60,
61–70 years). They identified 2,260 lung transplant
recipients (1,835 SLT, 425 SBLT) from 1991–1997 and
performed risk-adjusted survival analysis using Cox
regression, Kaplan-Meier analysis, and calculation of
risk ratios for mortality. Among all transplant recipients,
recipient age and procedure type (SLT vs. BLT) were found
to be associated with increased risk for mortality, with
advanced age, SLT, and their interaction demonstrating
significant associations. On Kaplan-Meier analysis, the
authors demonstrated that BLT was associated with higher
survival in both the 41–50 and 51–60 years age categories
across all time points, with a more pronounced survival
benefit occurring further out from surgery. Survival rates
among younger patients (<50 years) who underwent SLT
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were 93.6%, 80.2% and 43.6% at 30 days, 1 year, and
5 years, respectively, compared to 94.9%, 84.7%, and
68.2% in the young BLT group (P=0.001). Among those
aged 51–60 years, the differences in long-term survival were
slightly less pronounced. Those who received SLT had
30-day, 1 year, and 5-year survival rates of 93.5%, 79.4%,
and 39.8%, respectively, compared to 93.0%, 79.7%,
and 60.5% for patients of similar age who received BLT
(P=0.05). After age 60, however, the trend reversed. Survival
associated with SLT was considerably higher (93.0%,
72.9%, and 36.4%) compared to BLT (77.8%, 66.0%, with
5-year mortality data unavailable) (P=0.2). When using
risk ratios to calculate risk of mortality across all ages,
the authors noted an increased probability of mortality
for recipients of SLT between ages 40–57 (P=0.001 at
each age). At approximately age 57, the trend reversed.
Additionally, the authors focused on US transplant cases to
examine 3-year morbidity associated with transplantation
technique. They measured events of hospitalization for
rejection, onset of bronchiolitis obliterans (BOS), bronchial
airway complications, and hospitalization for infections.
No significant differences were observed between BLT and
SLT in any of these measures. However, the study did not
measure variables associated with short-term morbidity,
which may be more relevant in older patients. The study
concluded that BLT was associated with greater short and
long-term survival in patients less than 60 years of age.
Thabut and colleagues confirmed the positive long-term
survival advantage that BLT offered to the younger COPD
population (9). They completed a large retrospective
analysis of the ISHLT registry between 1987 and 2006.
Thabut performed a survival analysis of 9,883 patients
with a diagnosis of COPD. Additionally, they documented
important trends in the use of BLT for COPD. For
example, the proportion of patients with COPD who
underwent BLT more than doubled from the 1990s to
more recently (21.6% in 1993 to 56.2% in 2006). Using
modern propensity score matching (a technique lacking
in previous papers on the subject) to control for possible
treatment selection bias associated with each transplant
method, Thabut determined that median survival time
was significantly greater for those who received BLT
( 6 . 4 1 y e a r s , 6 . 0 2 – 6 . 8 8 y e a r s ) c o m p a r e d t o S LT
(4.59 years, 4.41–4.76 years) (P<0.0001). However, the
survival advantage associated with BLT did not hold
for patients greater than 60 years of age. The practical
suggestion was similar: to offer BLT to younger COPD
patients but to accept the lack of a difference in older
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recipients and perhaps use other criteria to choose the
transplantation strategy in this population.
The authors’ institution (Washington University in
St. Louis/Barnes Jewish Hospital) is a high-volume lung
transplantation center, and BLT has been the preferred
transplantation method. Cassivi performed a 13-year review
of lung transplantation for COPD patients at BarnesJewish Hospital between 1988 and 2000 looking at inhospital mortality and 5-year survival rates among patients
with COPD and alpha-1-antitrypsin deficiency (10).
More than 70% of emphysema patients received BLT,
reflecting the strong institutional preference for the
method. Cassivi acknowledged that the preference for
BLT was due to a record of increased survival and ease of
postoperative ventilator management. When examining
long-term survival, COPD patients who received BLT had
significantly higher 5-year survival at 66.7% compared to
44.9% for single lung replacement (P<0.001). Conversely,
many other studies did not find the same survival benefit
conferred by BLT.
Bennett and colleagues performed a retrospective
single center review of COPD patients undergoing lung
transplantation, with a special focus on patients older
than 55 years of age (11). These authors noted that it was
standard policy since the inception of their transplantation
program to only perform SLT on emphysema patients
older than 55 years of age. They attempted to identify
specific patient subgroups that benefit from SLT. They
examined 5-year survival rates between patients receiving
SLT (206 patients) and BLT (30 patients) from 1992–2012.
As expected, the SLT cohort tended to be older and had
reduced pre-transplant pulmonary function and physical
conditioning compared to the BLT cohort. Within this
institution, 30-day, 1-year, and 5-year survival estimates
between treatment cohorts were similar, with long-term
survival trending slightly higher for BLT patients. Due to
their small pool of BLT patients, they also compared their
institutional data to the outcomes of SLT and BLT patients
in the UNOS registry. When comparing institutional data
to SLT and BLT patients in the UNOS registry, Bennett
noted that their own institution’s SLT patients had generally
similar preoperative risk in terms of advanced age, comorbid
condition, and pulmonary function. Their institution’s
SLT short and long-term survival rates were similar to
those of the UNOS registry’s BLT subset. This may reflect
improved experience and perioperative care, given that
SLT is their institutional preference. They concluded that
while BLT may provide an individual survival benefit, SLT
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had substantial utility and should be promoted as much
as possible given the overall impact that it can have in
increasing the number of patients receiving transplantation.
Several studies of BLT vs. SLT were performed on
institutional or national databases that captured data
before the 2005 implementation of the lung allocation
score (LAS). Schaffer compared SLT and BLT in the postLAS era (12). Using the UNOS registry from 2005-2012,
Schaffer compared graft survival between transplantation
types. Graft survival represented a composite of posttransplantation mortality and graft failure rates. These
patients were propensity matched to reduce the impact
of treatment selection bias on the results of the study.
Among 3,174 COPD patients, 1,299 underwent SLT and
1,875 underwent BLT. The median follow-up was carried
over 2 years post-transplant, and there was no significant
association found between type of transplant and median
graft survival (67.7 months for BLT vs. 64.0 months for
SLT; P=0.23). This distinction from previous study results
may be explained by the novel way that patients were
selected for transplantation using the LAS. Compared to
the pre-LAS era, during which time on the waiting list gave
priority for transplantation, patients with COPD in the
LAS era must be comparatively more impaired to achieve
a higher transplantable score (13). The use of the LAS to
prioritize recipients for transplantation may have reduced
the apparent benefit of BLT for patients with COPD.
ILD and interstitial pulmonary fibrosis (IPF)
ILD, which includes IPF, carries the worst overall prognosis
among end stage pulmonary disease indications for lung
transplantation (14). Median survival time for patients with
IPF ranges from 2–3 years post diagnosis without lung
transplantation, with 5-year post-transplant survival rates
ranging from 30–50% (14,15). Non-surgical therapies are
limited (14,16). Lung transplantation has thus far been the
only restorative therapy to offer a proven survival benefit.
The short natural history of IPF without transplantation
gave that diagnosis a competitive edge when the LAS was
rolled out in 2005. With the application of the LAS in the
United States, the rate of lung transplantation in this IPF
population has risen dramatically. Despite the rising number
of lung transplants in patients with IPF, there is no definitive
survival advantage consistently shown to be associated with
either BLT or SLT. Overall, however, the use of BLT in
patients with IPF is on the rise. In 2011, approximately
54% of lung transplant operations among IPF patients were
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bilateral (17). In a retrospective institutional case series
performed at Cleveland Clinic, Mason and colleagues [2007]
studied 82 patients who underwent lung transplantation
for IPF (18). They compared overall 30-day, 1-year, and
5-year survival between patients with IPF and propensitymatched, non-IPF patients. Overall survival among IPF
patients was significantly worse at all time points compared
to their non-IPF matched counterparts. Additionally, they
calculated that BLT conferred a survival advantage among
IPF patients (81% vs. 67% and 55% vs. 34% at 1 and
5 years, respectively). However, they could only compare
BLT versus SLT in 10 matched pairs due to the strong
selection bias attributed to their institutional preference
to perform BLT in younger patients. Interestingly, they
failed to note advanced age as an independent risk factor for
mortality in BLT.
Additional studies have also supported the use of BLT
in IPF patients because of an apparent survival advantage.
Weiss focused on transplantation in IPF patients after the
institution of the LAS score (19). They examined all-cause
mortality 1-year after transplant in 1,256 IPF patients listed
in the UNOS registry between 2005 and 2007. Additionally,
they further examined the effect of pre-transplant disease
severity on mortality outcomes by stratifying patients into
LAS quartiles. Quartiles 1–3 indicated lower risk IPF
patients, while quartile 4 contained the highest risk IPF
patients. They determined that IPF patients with higher
LAS were more likely to receive BLT. They observed a
trend towards greater usage of BLT in sicker patients,
with 21% more patients receiving BLT in the highest LAS
quartile compared to the lowest (59.5% vs. 38.4%, P<0.05).
Within the highest quartile, SLT was associated with a
14.4% increased risk in cumulative mortality compared to
BLT. However, in the lowest quartile, SLT was found to
be an independent protective factor in terms of mortality.
There was no demonstrated short-term survival benefit
associated with either transplantation type. Their findings
are counterintuitive to the notion that BLT should be
reserved for younger patients with more physiologic
reserve, and instead suggest a role for BLT specifically for
those with potentially higher pre-operative risk.
Force conducted one of the largest retrospective reviews
of lung transplantation among IPF patients (20). This report
also demonstrated a survival advantage associated with BLT
among IPF patients. The authors performed a retrospective
review of the UNOS registry from 1987 to 2008 studying
3,860 patients (2,431 SLT and 1,429 BLT) using propensity
score matching. Propensity-matched analysis failed to show
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a substantial survival benefit for BLT (HR 0.90, 95% CI,
0.78–1.0, P=0.11). However, when a one-year conditional
survival analysis was performed, the authors found that BLT
had significantly better long-term survival (12.08 versus
6.8 years, P=0.0006). When analyzing for risk factors for
death within the BLT group, they reported recipient age,
donor age, and year of transplantation to be significant
predictors of mortality. Specifically, they observed that
patients over the age of 57 had higher 1-year post-transplant
mortality risk. Based on the conditional survival analysis
and the significant correlation between advanced age and
mortality risk, the authors concluded that younger IPF
patients would most likely benefit from BLT to enhance
long-term survival.
Not all available studies found a survival advantage
associated with BLT. Chauhan performed a review of the
UNOS registry from 2001–2009, examining actuarial posttransplant graft survival (21). In a unique approach, they
studied 1,001 lung transplant recipients with IPF who
were concurrently listed for BLT and SLT. Four hundred
thirty-four (43%) of these patients underwent SLT while
the remaining 57% underwent BLT. The authors noted
significant differences in baseline comorbidities, functional
status, pulmonary function tests, and recipient disease
severity. Despite these baseline differences, there were no
observed differences in short or long-term graft survival.
Based on these comparable outcomes, the authors advocated
for more liberal use of SLT among IPF patients. However,
they did note that a major limitation of their study was
the assumption that organ assignment was random and
based solely on the availability of one or two donor lungs.
At the institutional level, or even the surgeon level, there
may be great variability in willingness to accept any
individual donor lung based on several donor and recipient
characteristics. For example, a hospital may list a patient
for either SLT or BLT, suggesting equipoise, but that
same group may have a low threshold to decline a single
lung donor. This effectively would make their original
assumption about the equivalence of the transplanted lungs
less valid.
Meyer performed a large-scale retrospective review of
the early UNOS registry experience in 2001 that included
a cohort of 821 lung transplant patients (636 SLT, 185
BLT) with pulmonary fibrosis (4). They produced an agestratified comparison of survival by procedure type. On
crude univariate analysis, they found that younger IPF
patients (30–49 years) with SLT had better short and longterm survival post-transplant than similar patients after
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BLT (90.9% vs. 77.1% at 1 month; 63.8% vs. 46.2% at
3 years; P=0.02). The same trend favoring single lung
replacement was observed in older patients. However, when
a 1-month post-transplant conditional survival analysis
was performed, there were no significant subsequent
differences seen between procedure types at any age group.
This suggests that there may be greater periprocedural
mortality associated with BLT. Propensity score matching
and multivariate regression analysis failed to show survival
differences between procedure types. Nwakanma focused
their analysis on bilateral versus single lung transplants in
IPF patients older than 60 years of age (22). Performing
a large-scale analysis of 1,656 IPF patients in the UNOS
registry between 1998 and 2004, they concluded that SLT
was favored in this age group, with 78% of the patients
in that sample undergoing SLT. Propensity score analysis
demonstrated similar short and median-term survival
between BLT and SLT. Transplantation type was not
associated with mortality. Thus, they could not advocate for
the use of either procedure type in older IPF patients.
When examining diagnosis-specific survival outcomes
for BLT versus SLT, the existing literature demonstrates
mixed findings. Comparing bilateral and single lung
transplant effects by indication is crucial as the underlying
pathophysiology of each disease is very different, and could
greatly affect outcomes. The use of bilateral transplant for
both COPD and IPF is on the rise. Both techniques have
been utilized in younger and older populations despite
previous notions that older individuals may “lack the
reserve” to tolerate the procedure (4,9,10,19,20). Some data
have demonstrated a greater advantage for using bilateral
transplant in younger COPD populations, but the evidence
in that disease is still conflicting (4,9). The picture is even
more mixed in analyses of IPF patients. The available
literature is relatively lackluster because most studies are
small, retrospective, single-center case reviews. These
studies are often limited in sample size and may be affected
by institutional comfort and experience with a preferred
technique. Other studies have relied on large retrospective
database analysis of the ISHLT and UNOS registries, and
many are based on data obtained before the institution of
the LAS prioritization scheme. With the implementation
of the LAS, the patient characteristics of those undergoing
transplant are different, with a priority given to those with
higher severity of illness instead of longer time spent on the
waitlist (12). A randomized control trial is neither practical
nor feasible in this setting. High quality, prospectively
collected data collected from a variety of institutions that
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comprehensively take into account the effects of age and
multiple comorbidities will be useful in further unmasking
the effect of transplantation type for advanced COPD
and IPF patients. Until that time, the data are diverse and
conflicting enough to simply state that there is equipoise
between the two strategies. Factors other than patient
survival or graft survival must be considered as well.
Post-transplant functional status and procedure
type
In addition to collecting data on short- and long-term
survival, several authors have examined the influence
of BLT versus SLT on post-transplantation functional
status. Functional status is most commonly quantified by
spirometry, which has been strongly correlated with QOL
in lung transplant patients (23). However, other measures
such as the 6-minute walk test (6MWT) and comprehensive
surveys on each patient’s ability to perform daily activities
have also been used. Mason and colleagues performed
a single institution study of the relative impact of lung
transplantation on recipient pulmonary function, with a
particular focus on measuring percent-predicted forced
1-second expiratory volume (FEV1%) (24). They had 9,471
postoperative FEV1 and forced vital capacity (FVC) values
from 509 adult transplant recipients, and performed a
longitudinal temporal evaluation of FEV1% values for each
patient. Mason and colleagues found that for both BLT
and SLT patients, FEV1% typically peaked at 1 year after
transplant. Forced 1-second expiratory volume increased
from 50% in the immediate postoperative period to 55%
at 1 year post-operatively in SLT recipients, and then
gradually declined to 47% by three years. BLT recipients
exhibited a similar trend but had higher overall FEV1 values
at every time point (60% immediately post-transplant, 75%
1-year post-transplant, and 65% 3 years post-transplant).
The authors also noted an increased mortality risk
associated with decline in post-transplant FEV1 values in
all recipients. Although patients undergoing either SLT or
BLT exhibited increased risk of death with declining FEV1,
this association in BLT recipients was notably tempered.
The authors suggested that BLT may confer a protective
effect on FEV1—and thus survival—likely as a function
of providing recipients with enhanced pulmonary reserve.
They recommended consideration of functional status in
identifying which age groups would obtain maximal benefit
from lung transplantation.
Pêgo-Fernandes also demonstrated relative improved
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pulmonary function (as measured by spirometry) among
patients who underwent BLT (23). They performed a
small, single-institution review of FVC and FEV1 data
among lung transplant recipients between 2003 and 2006.
Twenty-nine patients underwent transplant and were alive
after the first postoperative year, and were thus included
in analysis. Of these, 11 patients underwent SLT and 18
patients underwent BLT. All patients underwent spirometry
pre-transplantation, and at 1-, 3-, 6-, 9-month, and 1-year
intervals post-transplantation. Baseline characteristics of
each cohort showed that patients who underwent BLT
were younger but had significantly worse pre-transplant
pulmonary function (mean FEV1 23.68 in BLT patients
versus 44.11 in SLT, P<0.001). Similar to the findings
demonstrated by Mason and colleagues, FEV1 and FVC
peaked at 1-year post-transplantation for all transplant
recipients. The BLT group had proportionally higher
1-year post-transplantation FEV1 values. The authors
hypothesized that worse spirometry results among SLT
patients could be attributed to hyperinflation or progression
of the underlying disease in the native lung. However, the
extremely small sample size of each cohort should be noted.
Pochettino observed improved pulmonary function
and exercise tolerance in COPD recipients of bilateral
transplantation (25). Similar to previous studies, they
performed a single center retrospective study of 130 patients
with emphysema from 1991–1999. Eighty-four patients
underwent SLT and 46 patients underwent BLT. In addition
to survival, the authors measured secondary outcomes of
spirometry and 6-minute walk distances pre-operatively
and at 3- to 6-month intervals post-operatively. While
the authors prefer BLT (especially in younger patients)
given their own institutional experience, they had utilized
SLT on a more frequent basis due to scarcity of available
donors. BLT was rarely utilized for recipients >60 years of
age. Baseline FEV1, FVC, and 6-minute walk scores were
similar between cohorts. At all post-transplantation time
points during a 4-year observation period, BLT recipients
exhibited higher FEV1 and FVC values compared to
SLT, despite having similar baseline pulmonary function.
Additionally, BLT patients had a higher mean 6-minute
walk distance at all follow-up time points compared to
SLT patients, with the difference ranging from 100 to
400 feet. It should be noted that the comparisons of
spirometry values and exercise tolerance in this study were
not adjusted for confounding characteristics. For example,
with the authors favoring the use of SLT in older recipients,
the BLT recipients were measurably younger (51.1 versus
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56.2 years, P<0.0001). In this sense, the SLT cohort was
preferentially burdened by a group of patients with more
advanced age, and presumably more comorbidities and
frailty. Further assessment of comorbidity or pre-transplant
disease severity was not performed. The authors concluded
with their preference for BLT in younger recipients due
to the superior functional results and quality-of-life payoff
the bilateral approach affords. The degree to which their a
priori programmatic adoption of a BLT strategy for younger
recipients created this appearance of improved function is
impossible to measure.
Gerbase performed a combined prospective analysis
of post-transplantation functional status and QOL (26).
Focusing on spirometry and 6-minute walk distance,
they prospectively enrolled 44 patients prior to lung
transplantation. Fourteen (32%) eventually received
SLT, while the remainder received BLT. Spirometry
measurements and exercise assessment were performed
before the transplant, as well as 6 and 12 months posttransplantation. Patients included in the report were
followed for at least 2 years post-transplantation, raising
some concerns about “survivor bias” and challenging the
degree to which the result apply to patients on the waiting
list. Although transplantation provided higher FEV1%
predicted compared to baseline in all patients, this effect
was dramatically lower among SLT recipients. At each time
point over four years post-transplantation, SLT patients
consistently had spirometry values at least 20% lower than
spirometry scores of BLT recipients. 6MWT distances were
not significantly different between cohorts, however.
Instead of spirometry, Genao utilized a comprehensive
performance score (Karnofsky performance score,
KPS) to gauge functional status in older lung transplant
recipients (27). Genao wanted to characterize the longterm (1–5 years post-transplantation) trajectory of physical
function, and subsequently analyze trends in older
(>65 years) recipients of single and bilateral lung
transplants. The authors performed a retrospective review
of 4,805 patients listed in the UNOS registry between
2005 and 2009. Of these, 774 patients were at least 65 years
of age, and 63% of this older subset received SLT. They
began their analysis at 11 months post-transplantation
based on the assumption that all patients would naturally
undergo a postoperative period of disability and functional
recovery within the first year after transplantation. KPS
were assessed for all patients. The KPS was initially
developed in the 1940s, and was a clinician-rated measure
that estimated the patient’s ability to conduct his or her
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daily activities/self-care with none, some, or complete
assistance. The score ranges from 0 to 100, and a score of
60 or less was traditionally associated with a higher risk
for hospitalizations, the need for clinic visits, a serious
functional decline, or mortality (28). The authors found
that mean KPS scores at 1-year post-transplantation were
higher than seen prior to transplantation for all recipients.
One-year post-transplantation KPS was, on average, 2.6
points higher (on the scale of 100) for BLT than SLT
recipients (P<0.0001). In subsequent years, there was an
average 3.2 points decline for all patients, regardless of
transplantation type. While BLT was associated with higher
KPS post-transplantation, the authors noted that it was very
rare for patients of either group to reach a level of disability
predictive of poor outcomes (KPS ≤60) within the 5-year
follow-up period. Thus, Genao and colleagues were unable
to support the use of BLT in older recipients based on
predicted KPS scores. There were important limitations to
this study. The authors cautioned that conclusions regarding
use of BLT vs. SLT based on their findings should be
tempered, as they were unable to control for comorbidities
or provider preference. Additionally, the study took into
account the immediate perioperative functional decline
associated with the recovery period of transplantation
and included only patients were alive and had KPS scores
after 11 months post-procedure. However, they did not
discuss how they handled longitudinal measurement of
KPS scores in patients who died after the 11-month cutoff.
If QOL measurements were only taken from those who
survived, there could be a survivor bias associated with the
results. Additionally, the authors mention that the KPS is
a clinician-based assessment, and is not a patient reported
outcome instrument. Clinician assessment of a patient’s
QOL can vary from the individual patient’s experience and
the clinician might be biased when assigning such scores.
Post-transplantation QOL outcomes
For most patients with end-stage lung disease, lung
transplantation cannot only provide a survival advantage,
but can also influence dramatic changes in health-related
QOL (HRQL). The most significant gains in HRQL are
expected to be seen in physical health and functioning,
and the greatest improvements are expected to occur early
(within the first 6 months) after transplant (26). After
1 year, the risk of onset of BOS and the effect of other
patient comorbidities can blunt the effect of transplantation
on HRQL (29). Research into patient-centered outcomes
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in the field of lung transplantation has received growing
attention over recent years. However, the available
literature on this topic is relatively lacking, and there are
even fewer studies that attempt to examine the influence of
transplantation type on QOL.
Certain cross-sectional studies have asserted a positive
effect of BLT on HRQL measures. Anyanwu performed
a European multicenter cross-sectional study of 255 lung
transplant recipients (30). They administered the EuroQOL
5D (EQ5D) and visual analog scale (VAS) health-utility
instruments to patients who received bilateral (n=79), single
(n=106) and heart-lung (n=70) transplants. The EQ5D
defines health quality in five dimensions: mobility, selfcare, usual activities, pain and discomfort, and anxiety or
depression (30,31). Survey takers can assign one of three
labels to each dimension: no problem, moderate problem,
or severe problem. Utility scores can then be assigned
to each of these health states using regression analysis.
The VAS allows participants to subjectively assess their
own health on a scale of 0 to 100 (worst possible health
to best possible health). In addition to stratifying results
by transplant type, the authors repeated surveys at four
different post-transplant time periods: 0–6, 7–18, 19–36,
and >36 months. Problems in all five EQ5D domains in all
time periods were more common among SLT patients than
BLT patients. Those who received bilateral or combined
heart-lung transplants had significantly higher EQ5D
and VAS scores than their SLT counterparts in all time
groups after 6 months (P=0.001). However, this study was
limited by the lack of controlling for age and pre-transplant
diagnosis.
The positive impact of BLT on HRQL was not
demonstrated by all studies. Gerbase administered the
St. George’s Respiratory Questionnaire (SGRQ) and the
VAS to 34 patients who had undergone SLT (n=14) or
BLT (n=30) (26). The SGRQ primarily addresses three
areas: respiratory symptoms, accomplishment of routine
activities and disease impact on daily life (32). These
patients were followed for at least 2 years (when the authors
believed average onset of BOS occurs) and all data were
collected prospectively. The authors noted that SGRQ and
VAS scores were significantly improved after transplant
compared to pre-transplant in both SLT and BLT groups.
However, post-transplant, there was no significant
differences in QOL scores between SLT and BLT groups.
Scores were also independent of the underlying disease
that led to transplantation. As described in the previous
section, the authors also collected spirometric and 6MWT
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data and found that the post-transplantation improvement
in FEV1% predicted scores were significantly less in SLT
versus BLT recipients. 6MWTs were comparable between
cohorts. The authors suggested that pulmonary function
had limited influence on objective and subjective parameters
of patient health-related QOL.
Copeland prospectively studied QOL measures in
patients who were 1-year post-transplantation (33). They
utilized a pre-existing study cohort of 131 lung transplant
patients who were already prospectively enrolled in a
cytomegalovirus (CMV) prevention trial. To obtain data on
physical and mental health QOL measures, they surveyed
these patients immediately pre-transplant, as well as 3, 6, 9,
and 12 months after transplant using the Medical Outcomes
Study 36-Item Short-Form Health Survey (SF-36).
As a part of the SF-36, scores are assigned to develop the
Physical Component Survey and Mental Component
Survey (34). These scores were followed longitudinally
over the first post-transplant year. The authors used linear
mixed modeling for repeated measures of QOL scores,
which relied on any data collected at any time point to
longitudinally estimate scores. This approach was used
because the authors anticipated missing data from loss
to follow-up or death. Over this time period, Physical
Component Survey scores rose by an average of 10.9
points from baseline (P<0.0001), reaching a level close
to the average US population score. Mental Component
Survey scores did not exhibit a significantly dramatic rise.
When stratified by transplant type, bilateral operations
did not confer a significant advantage in gains in physical
component scores over single lung transplant. Given that
the functional outcome benefit conferred by bilateral
procedures has been shown to be greater in the long term
(>1 year), it would be interesting to see if there would be a
clinically important difference in QOL scores if they were
longitudinally followed over a longer period of time.
Associations between procedure type and
chronic rejection
BOS syndrome after lung transplantation represents
chronic allograft rejection and dysfunction (35). BOS
syndrome is defined as a progressive airflow obstruction
with deterioration of graft function, and affects up to 60%
of lung transplant recipients who survive 5 years posttransplantation (36). The mean time between transplant
and diagnosis is approximately 16–20 months (35). It
has been characterized by a continuous deterioration in
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FEV1% predicted, and can be pathologically confirmed by
the presence of intraluminal fibromyxoid granulation tissue
and extensive eosinophilic infiltrates on transbronchial
biopsy (37).
BOS has been linked to many poor outcomes in transplant
recipients, with increased mortality risk and an association
with decreased functional and HRQL outcomes (35).
While the exact physiologic mechanism behind the
development of BOS is unknown, multiple studies
have reported SLT as a risk factor for development of
BOS (26,38,39). Neurohr and colleagues performed an
institutional review of their lung transplant database and
compared 46 SLT and 30 BLT recipients with a diagnosis of
IPF (38). SLT was found to be a predictor for occurrence of
BOS ≥ stage 1. Another small institutional study performed
by Gerbase, who noted that risk of BOS development at
24 months post-transplant was more than two times higher
in SLT recipients (RR 2.86; 95% CI, 1.22–6.67) (26).
Hadjiliadis found SLT to be independently associated with
BOS occurrence after transplantation (39). In their single
center retrospective study of 225 transplant recipients, they
found an overall incidence of BOS to be 41.3% at a median
time of 4.2 years since transplant. After controlling for other
patient comorbidities and characteristics, SLT was found to
be significantly associated with BOS onset in multivariable
regression analysis. Other variables including transplant
center, recipient age, and end-stage lung disease diagnosis
were not associated with risk of BOS development. As
diagnosis of BOS depends on the decline in FEV1%, it
makes sense that SLT patients are at increased risk of BOS
development. Unlike BLT patients, SLT patients still have
a diseased native lung, and its deterioration over time
contributes to their overall FEV1%. Thus, in a hypothetical
situation where the recipient risk factors and donor lungs
are equal, an SLT patient may have a higher baseline risk
for meeting the threshold of a BOS diagnosis compared to a
BLT patient simply due to native lung dysfunction.
Transplant center, recipient age, re-sapient diagnosis,
gender, acute rejection score and number of bronchoscopies
in the first 6 months had no effect on the risk of BOS
development.
Not all studies have demonstrated the same association
between transplantation type and onset of BOS. In a much
larger UNOS database analysis of 2,260 lung transplant
recipients with primary diagnosis of COPD, Meyer and
colleagues did not observe a difference in BOS incidence
between SLT and BLT cohorts over the three-year followup period (4). Given the enormous morbidity and mortality
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burden that BOS imposes on lung transplant recipients,
further research is warranted to investigate the physiologic
mechanism of BOS and any possible link there may be to
transplantation type.
Ethical considerations
Much of the debate surrounding use of BLT or SLT stems
from the ethical challenge of how best to make use of
a limited resource: donor lungs. The persistent ethical
dilemma surrounding lung transplantation is whether the
possible broader societal benefits of splitting a pair of donor
lungs and thus reducing wait list time and wait list mortality
outweighs the cost to the individual recipient to forego
BLT. Several institutions, including our own, routinely use
BLT for most lung transplant recipients (10). This brings
to head the ethical dilemma posed by BLT, and challenges
the reader to decide whether increased individual benefit is
worth the societal cost of fewer patients transplanted.
Several groups have found innovative methods to
determine the opportunity cost of providing bilateral
operations. Anyanwu examined lung donors reported to the
United Kingdom Cardiothoracic Transplant Audit between
1995 and 1998 for whom both lungs were utilized (40).
They examined survival, rejection, and infection of donor
recipients of these lungs to make comparisons between
single lung and bilateral lung recipients. One-year graft
survival for single lung and bilateral lung blocks were
similar (65% vs. 71%). Of donor blocks that went to SLT
recipients, both grafts were functioning in 44% of donor
blocks, both grafts failed in 14% of donor blocks, and one
of the two lungs failed in 42% of donor blocks. The authors
estimated that splitting a lung block for SLT produced 1.8
survivors per donor block at 1-year post-transplant. One of
the weaknesses in their study is that they did not stratify by
clinical diagnosis, and they even included a large number of
patients with CF and those undergoing re-transplantation
in their analysis. In another study, Anyanwu and colleagues
examined cost-effectiveness of transplantation versus
medical therapy, and included additional comparisons of
SLT and BLT (41). They determined that over a theoretical
15-year period, transplantation (compared to remaining
on the waitlist with medical therapy) provided 2.1 and
3.3 quality-adjusted life-years (QALY) for SLT and BLT,
respectively. The average cost of medical therapy for those
not receiving a transplant during this period of time was
$73,564. The costs of SLT and BLT were $176,640 and
$180,528, respectively. Costs per each QALY gained were
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$48,241 for SLT and $32,803 for BLT. Based on the cost
per QALY gained, the authors concluded that SLT was the
least cost-effective form of therapy for patients with end
stage lung disease. However, they noted that they were
unable to quantify the additional societal gain that would
come from the SLT’s ability to treat more patients. Also,
it may be possible that the cost to society would be more
accurately measured in total cost and not cost per QALY. A
plan of more single lung transplant operations will lead to
more operations in general and more patients on the very
expensive post-transplant medications. The broad use of
single rather than bilateral operations could greatly increase
the total cost of lung transplantation programs to a society
or a payer.
Wang took into account not only the ethical challenges
in offering one versus two lungs, but the effect of remaining
on the transplant waiting list longer with the hopes to
undergo bilateral transplantation (42). Utilizing data
obtained from national UK transplant database, they
performed a sequentially stratified proportional hazards
model on 1,211 adult lung transplant patients to address
the following question: “should I accept SLT if offered
or should I remain on the waiting list in the hope that
I will be offered BLT in the future.” They found that
in patients with pulmonary fibrosis, SLT was associated
with a significant reduction in mortality hazard relative to
waiting for BLT (HR 0.81, 95% CI, 0.68–0.97, P=0.021).
They concluded that for pulmonary fibrosis patients,
accepting SLT outweighed remaining on the transplant
list for a BLT by minimizing the high pre-transplant risk
of death. There was no such benefit demonstrated in
accepting SLT for patients with COPD, however. Munson
and colleagues reached a different conclusion (43). They
created a simulation of a lung transplant waitlist using
actual post LAS implementation UNOS registry data to
define waitlist size, donor frequency, waitlist mortality risk,
and disease- and procedure-specific post-transplantation
survival. They aimed to determine post-transplant survival
associated with BLT versus SLT in the COPD population.
They determined that SLT always increased the number
of patients transplanted, without significant reductions
in total post-transplant survival. A theoretical policy of
uniform use of SLT in their model resulted in an absolute
reduction in the risk of waitlist mortality of 4.2% among
all listed patients. However, they noted that this pattern
may not be reproducible once geographic donor variations
are accounted for and could not be compared to other
transplant disease indications.
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While the common ethical argument suggests that
SLT may provide greater societal benefit by maximizing
utilization of the existing donor pool, this may not be an
accurate depiction. One study used the UNOS registry to
study lung block utilization in all SLTs performed between
1987 and 2011. There were 7,232 unique SLT donors
identified. Of these donors, only 3,129 (43%) had both
lungs used for SLT. The authors reported that more than
200 potential donor lungs went unused annually since
2005. Donor factors associated with the harvest and use
of only one lung included type B/AB blood group, lower
BSA, lower pO 2, pulmonary infection, extended criteria
donor status, and traumatic brain injury or anoxia as cause
of death. This study challenged one of the long-standing
utilitarian arguments in favor of SLT (44).
At our own institution, there is a greater preference to
perform BLT in part due to the prevailing notion that two
lungs provide patients with greater physiologic reserve (10).
Given this assumption, we often use what might be
considered “marginal” donor lungs for BLT for patients—
donor organs that would otherwise might be wasted if
considered individually in single lung blocks and thus
declined. Similarly, in geographic situations in which donor
lungs are not considered by a large number of programs, the
ability to use two lungs might allow a physically small donor
to provide lung transplantation for a much larger recipient.
Therefore, it is possible that there is an occasional situation
in which the use of donor lungs is “both or none”. In this
sense, BLT may expand donor lung utilization. Further
research into the use of marginal donors/extended donor
criteria and subsequent impact on lung resource allocation
will be necessary to clarify the nuances in the BLT vs. SLT.
The ethical considerations of BLT vs. SLT encourage
surgeons and institutions to determine priorities: optimizing
total number of potential recipients who get transplanted or
enhancing post-transplant survival. It is likely that these two
goals might be at odds with each other. While adopting SLT
will definitely increase the number transplanted, this may
come at the expense of post-transplant long-term survival.
Implementation of the LAS on transplant lung allocation
practices aims to reduce transplant waitlist mortality.
However, much of the ethics surrounding the debate will be
expressed by institutional preference and practice.
The native lung: potential complications and
risk of cancer
One special consideration for the use of SLT is the risk
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of potential complications in the native lung. Native
lungs already have diminished lung function secondary
to underlying disease process, and the use of SLT can
potentially impose the additional complications. Venuta
and colleagues described their experience in native lung
complications in an institutional review (45). From
1991–1997, they reviewed 35 patients who received SLT,
of which 11 patients experienced an early (<6 weeks)
native lung complication. These complications included
overinflation, pneumothorax, hemothorax, pneumonia,
invasive aspergillosis, and active tuberculosis (which
was present at time of initial transplant). These patients
underwent a mix of medical and surgical therapy, with
3 patients receiving an operation. Mortality was still high,
with 6 of these patients dying within 6 months. King and
colleagues also described their institutional experience
with SLT, and also studied outcomes of pneumonectomy
for native lungs that experienced complications (46). In
180 single lung transplants performed from 1998–2008,
25 patients (14%) experienced significant native lung
complications. Of these, 11 patients went on to receive
a pneumonectomy for non-small cell lung cancer
(NSCLC), aspergilloma, bronchopleural fistula, and
recurrent infection. Complication rates after receiving
pneumonectomy were high (36.4%), but there was no inhospital mortality. Additionally, when comparing patients
who received a pneumonectomy for a complication to
those who did not experience a complication, there was
no statistically significant difference in median survival
(4.3 vs. 5.1 years). Thus, King concluded that while native
lung complications impose serious morbidity and mortality,
pneumonectomy could provide an acceptable solution.
While these studies highlight the potentially serious
morbidity and mortality of native lung complications,
certain points should be noted. First, the data presented in
these studies are of limited sample size and are relatively
outdated. The perioperative management of transplant
patients has undergone substantial improvement over the
years, calling into question whether high volume SLT
centers today would experience the high rate of native lung
complications. While early recognition and management
of native lung complications is important, the possibility of
developing a native lung complication does not necessarily
preclude the use of SLT.
One additional concern regarding SLT is the risk of
cancer development in the native lung. Citing increased risk
associated with long-term chronic lung disease, possible
recipient smoking history, increased age, and potential
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adverse effects of immunotherapy, one review documented
a 9% prevalence of primary lung cancer found in native
lungs after SLT (47). Olland and colleagues acknowledged
that surgical resection for early stage NSCLC of the native
lung should be pursued when possible, but the effects of
chronic lung disease and immunosuppression may make
surgery more challenging than when compared to a nontransplanted patient (47). Nevertheless, the benefits of
a SLT may still outweigh the risks of a BLT in a patient
with high LAS. Appropriate resource utilization should be
geared towards thorough and aggressive surveillance for
malignancy in high-risk SLT patients.
Future directions: SBLT?
As a possible compromise between SLT and BLT, Hartwig
and colleagues have proposed SBLT for high-risk patients
with ILD (48). To mitigate perioperative morbidity
and mortality risk and to preserve the observed longterm benefit of BLT, these authors proposed utilization
of SLT in some recipients and then relisting them for a
subsequent contralateral SLT at a future date. Typically, an
institution using this strategy will list individuals deemed
to have higher perioperative risk (by age or comorbidity)
to undergo SLT. After transplantation, these patients are
reviewed for re-listing and all individuals who were noted
to have acceptably low perioperative complications and
reasonable functional status were considered. Re-listing
for contralateral transplant was performed as soon as was
clinically appropriate (as determined by adequate functional
recovery and no presence of infection or rejection). The
authors performed a matched cohort analysis with a primary
outcome of survival. Twelve patients underwent SBLT,
and matches were selected in a 1:2:2 ratio from SLT and
BLT recipients with ILD and similar LAS score. When
comparing characteristics between the first and second
stages of the SBLT procedure, there were no significant
differences between donor characteristics. LASs were
significantly higher in the first stage compared to the
second stage (48.6 vs. 24.5, P<0.01). When comparing
between matched cases, the authors found no significant
differences in survival. The authors thus proposed SBLT
as an alternative to SLT and BLT. The concept of SBLT is
intriguing, but the strategy itself is fraught with potential
complications and ethical challenges. The authors noted
that the staged bilateral option exposes patients to two
operations, and there may be a pool of individuals who
sustain the risks of a second procedure when they could
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have done reasonably well with just the initial single lung
transplant. Additionally, the existing knowledge on the
immunologic consequences of receiving a second lung
from a separate donor is relatively limited. It is unclear
whether these patients will be at greater or reduced risk for
developing lung allograft dysfunction long-term. From an
ethical perspective, it is unclear whether SBLT truly results
in a better redistribution of a limited resource. While
more lungs would be available for use if individuals
underwent a unilateral first stage operation instead of a
BLT, many would ultimately reappear on the waitlist. It
is unclear whether the second donor lung would achieve
more benefit as a second implant for a staged procedure
recipient or being utilized for a new patient who has
never undergone transplantation. Although several
important questions regarding use of SBLT exist, it still
remains a controversial option and further investigation
into the subject may be warranted.
Conclusions
BLT has grown in utilization among transplant centers
nationally, and presents a useful option for patients with a
variety of end-stage lung disease diagnoses. The increased
adoption of BLT is likely reflective of increased comfort
in practice among transplant surgeons and recognition of
benefits measured by long-term survival and improvements
in functional and QOL outcomes. However, much of
the literature that examines the use of BLT versus SLT
is conflicting, and the clinical picture is further nuanced
by disease indication, age of recipient, donor lung quality
and patient disease severity. Although it is our institutional
preference to utilize BLT in our patient population when
possible, we cannot recommend one procedure type
over another given the lack of high quality evidence.
Transplantation type will continue to be determined
on an individual basis. The current clinical picture of
transplantation in the post-LAS era is certainly different
than before, but much of the existing data available is not
yet reflective of this change. There will likely never be
a randomized trial to clarify the respective roles of BLT
and SLT. However, further large database analyses and
prospective observational studies will be instrumental to
bring clarity to this debate.
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